A generally applicable synthesis has been developed for 2-substituted oxirane-2-carboxylic esters, which have attracted interest as inhibitors of carnitine palmitoyltransferase-1 (CPT-1) for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). The route involves alkylation of the dianion of 2-methyl-2-propen-1-ol (methallyl alcohol) followed by Sharpless epoxidation. The utility of the method has been demonstrated by the synthesis of (R)-Etomoxir, the best known member of this class of compounds, and ethyl (R)-2-[6-(2,4-dinitrophenoxy)hexyl]oxirane-carboxylate, previously synthesised only as a racemate. The high enantiomeric purity of the compounds has been demonstrated by formation of Mosher esters of the products of Sharpless epoxidation and analysis by 1 H NMR spectroscopy.
Introduction
The enzyme carnitine palmitoyltransferase-1 (CPT-1) catalyses the conversion of long-chain fatty-acid CoA esters, principally the CoA ester 1 of palmitic acid, to carnitine esters such as 2. The latter can enter the mitochondria, where they are converted back to CoA esters by another carnitine palmitoyltransferase, CPT-2 ( Figure 1 ). cardiac hypertrophy. 8 These side effects are due in part to the lack of selectivity (of Etomoxir 3a
and other similar compounds) for the liver isoform of CPT-1 (L-CPT-1) over the skeletal muscle isoform (M-CPT-1). M-CPT-1 is the major isoform in the heart, and unwanted inhibition of this isoform is a major factor in the side-effects. To overcome this, the L-CPT-1-selective inhibitor ethyl 2-[6-(2,4-dinitro-phenoxy)-hexyl]oxiranecarboxylic 4 ( Figure 2 ) was developed, although only as a racemate. 9, 10 (The free acid form, prepared via a silyl ester rather than the ethyl ester, was used for biological testing). Although Etomoxir 3a has not been accepted for use treating NIDDM, it has more recently shown potential as a treatment for chronic heart failure. 11 Combined with the demonstration with compound 4 that the side-effects of substituted oxirane-2-carboxylates can be overcome, it seems likely that these compounds and analogues will continue to attract attention. Hence, we have developed a new synthetic methodology for substituted oxirane-2-carboxylates, exemplified by syntheses of 3a and monochiral 4 [(R)-enantiomer 4a].
Sharpless product. Various other published syntheses introduce the chirality by enzymatic resolution 13, 14 and via a chiral auxiliary. 15 Sharpless epoxidation has been reported before in the synthesis of Etomoxir 3a, but the synthesis of the necessary precursor 7 was long and inconvenient. 16 Our synthesis of precursor 7 is just two steps, and the complete synthesis of 4-Chlorophenol 5 was alkylated with an excess of 1,5-dibromopentane, sodium hydroxide and a phase-transfer catalyst to give the bromide 6 in a slightly modified literature procedure. 17 This was used to alkylate methallyl alcohol, doubly deprotonated with butyl lithium in the presence of TMEDA. We found that this reaction can be facilitated by using 2.5 M butyl lithium diluted to 1.6 M with diethyl ether, and also by allowing the reaction mixture to warm from -78 °C to room temperature over one hour after addition of the bromide. The resulting allyl alcohol 7 was epoxidised under modified Sharpless conditions using L-(+)-diethyl tartrate as the ligand to give compound 8a, or using D-(-)-diethyl tartrate to give the (R)-enantiomer 8b (not pictured). These stereochemical outcomes are based on the accepted model. 18 Alternatively, epoxidation with mCPBA gave the corresponding racemate (compound 8c, not pictured). The final step in the synthesis was ruthenium-catalysed periodate oxidation of 8a and esterification of the resulting crude acid. We initially used diethyl sulfate but found that ethyl iodide was superior, being less toxic and easier to remove. The product (R)-Etomoxir 3a (or (S)-Etomoxir 3b, not pictured, from (R) epoxy alcohol 8b) was easily purified by chromatography on silica. Finally, (R)-Etomoxir 3a could if desired be hydrolysed using sodium hydroxide to give (R)-Etomoxir, sodium salt 10a (not pictured), and likewise (S)-Etomoxir 3b gave (S)-Etomoxir sodium salt 10b (not pictured).
The high enantiomeric purity of the Etomoxir 3a was proved by formation of an ester 9a of its precursor epoxy alcohol 8a with (R)-α-methoxy-α-trifluoromethylphenylacetic acid (Mosher's acid), 19 using diisopropylcarbodiimide as the coupling reagent and DMAP as catalyst (Scheme 2). Both 8a and its enantiomer 8b were converted to (R)-Mosher esters for comparison (compounds 9a and 9b respectively). The crude samples were analysed by 1 H NMR before purification, and the peaks of the AB system corresponding to the diastereotopic CH 2 group indicated in Figure 3 were carefully integrated. In both cases, a diastereoisomeric ratio of 98 : 2, corresponding to an e.e. of at least 96 % for 8a and 8b, was observed. The 1 H NMR spectra for these CH 2 groups are shown in Figure 3 . (not pictured), or mCPBA to give racemate 17c (not pictured). Enantiomeric purity (e.e. ≥96 %) was again proved by the formation of (R)-Mosher esters as above (not pictured, compounds 18a and 18b for the (S) and (R) enantiomers respectively in the experimental section). Epoxy alcohol 17a was oxidised and esterified under the same conditions which yielded Etomoxir 3a to give ester 19, and the protecting group was removed using tetrabutylammonium fluoride (TBAF) in THF to give alcohol 20. This alcohol should be used promptly as it appears to go off on standing.
The final step was the coupling of 20 with a source of the 2,4-dinitrophenoxy group to yield the target compound 4a. To achieve this, two approaches were examined: nucleophilic aromatic substitution with 2,4-dinitrofluorobenzene, and Mitsunobu reaction 21 with 2,4-dinitrophenol. The
Mitsunobu reaction, which has been used in the synthesis of 2-substituted-oxirane-2-carboxylates previously, 15, 22 was the better of the two, 2,4-dinitrofluorobenzene giving difficultto-reproduce results and sometimes yielding compound 4a contaminated with an unidentified impurity difficult to remove by chromatography. Overall, this route is slightly longer than the route which yielded Etomoxir 3a, but has the advantage that the use of the Mitsunobu reaction allows for the dereferal of the coupling of the aromatic group until after the formation of the oxirane-carboxylate portion of the molecule. This opens up the possibility of the synthesis of a wide variety of chemically sensitive or nonphenolic analogues.
Conclusions
In conclusion, we have developed a versatile and efficient route to 2-substituted oxirane-2-carboxylates, which should allow the synthesis of a broad range of analogues in enantiomerically pure form. In doing so, we have developed the shortest synthesis yet published of Etomoxir.
pressure chromatography using Davisil 40 -63µ silica gel, Fluorochem, Derbyshire, UK. Optical rotations were recorded at 589 nm.
1-Bromo-5-(4-chlorophenoxy)-pentane (6).
To NaOH (4.6 g, 115 mmol) in water (120 mL) was added 4-chlorophenol (6.48 g, 50.9 mmol) portionwise with stirring. Tetrabutylammonium hydrogensulfate (116 mg, 0.34 mmol) was added followed by 1,5-dibromopentane (28 mL, 47.5 g, 197 mmol), and the mixture was heated at reflux overnight. The mixture was allowed to cool and extracted with diethyl ether (3 × 100 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated to an oil which was heated in vacuo (10 mmHg, 140 °C) to remove excess 1,5-dibromopentane. The residual oil was purified by column chromatography on silica (eluting with diethyl ether-petrol, 5 : 95) to yield the title compound as a colourless oil, 12 
8-(4-Chlorophenoxy)-2-methylene-octan-1-ol (7).
To anhydrous diethyl ether (15 mL) was added n-butyllithium (44 mL of a 2.5 M solution in hexane, 110 mmol) under N 2 , and the resulting solution was cooled to -78 °C. Freshly distilled tetramethylethylenediamine (16.7 mL, 12.9 g, 111 mmol) was added dropwise and the mixture was allowed to stand for 10 min. Methallyl alcohol (4.6 mL, 4.0 g, 55 mmol) was added dropwise, and the mixture was stirred overnight and allowed to warm to room temperature. After recooling to -78 °C, 1-bromo-5-(4-chlorophenoxy)-pentane 6 (6.39 g, 23.0 mmol) in THF (15 mL) was added dropwise. The mixture was stirred for 1 h, warming to room temperature. Aqueous HCl (0.5 M, 50 mL) was added cautiously. The mixture was partitioned between water and diethyl ether, the layers separated and the aqueous layer re-extracted with diethyl ether (3 × 50 mL). The combined organic layers were dried (MgSO 4 ) and concentrated to a residue which was purified by column chromatography on silica (eluting with ethyl acetate-petrol, 10 : 90). 
Rac-{2-[6-(4-Chloro-phenoxy)-hexyl]-oxiranyl}-methanol (8c).
To an ice-cold solution of 8-(4-chlorophenoxy)-2-methylene-octan-1-ol 7 (1.5 g, 5.59 mmol) in dichloromethane (50 mL) was added m-chloroperbenzoic acid (c. 90% pure, 1.28 g, 6.7 mmol) in dichloromethane (50 mL) dropwise. The mixture was allowed to warm to room temperature and stirred overnight. After this period, analysis by TLC (ethyl acetate-petrol, 2 : 3) showed starting material remaining, so m-chloro-perbenzoic acid (0.20 g, 1.05 mmol) was added and the solution was heated at 40 °C for 1 h. The solution was allowed to cool and washed with aqueous Na 2 SO 3 (2 × 50 mL), aqueous NaHCO 3 (2 × 50 mL), and water (50 mL), then dried (MgSO 4 ) and concentrated to yield the title compound as a colourless oil, 1.60 g (99%), which gave essentially identical analytical data as the (S) enantiomer 8a. 
(R)-Mosher's ester of (S)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol (9a). To a solution of (S)-{2-[6-(4-chlorophenoxy)
-hexyl]-oxiranyl}-methanol 8a (150 mg, 0.53 mmol) in DMF (5 mL) was added (R)-(+)-α-methoxy-α-trifluoromethylphenylacetic acid (Mosher's acid, 500 mg, 2.06 mmol), DMAP (10 mg, 82 µmol) and powdered 4Å molecular sieves (50 mg), and the mixture was cooled to 0 °C under N 2 . Diisopropyl carbodiimide (0.3 mL, 243 mg, 1.93 mmol) was added dropwise, and the whole was allowed to warm to room temperature and stirred overnight. The mixture was poured into water and extracted with diethyl ether (2 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), saturated aqueous NaHCO 3 (20 Etomoxir (3a) . To a vigorously stirred solution of (S)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol 8a (1.6 g, 5.62 mmol) in tetrachloromethane (11 mL) and acetonitrile (11 mL) at room temperature was added sodium periodate (3.59 g, 16.87 mmol) in water (17 mL) followed by ruthenium trichloride trihydrate (32 mg, 0.12 mmol). After 6 h, the mixture was extracted with dichloromethane (2 × 40 mL), and the combined organic extracts were washed with brine (20 mL), dried (MgSO 4 ) and concentrated to a black residue. This was dissolved in anhydrous DMF (12 mL) and treated with ethyl iodide (0.80 mL, 1.56 g, 10.0 mmol) followed by portionwise addition of KHCO 3 (0.68 g, 6.7 mmol). The mixture was stirred overnight, poured into water and extracted with hexane (3 × 40 mL). The combined hexane layers were dried (MgSO 4 ) and concentrated to a residue which was purified by column chromatography on silica (eluting with diethyl ether-petrol, 20 : 80) to yield the product as a colourless oil, 0.98 g (53%); R f 0.36 (diethyl ether-petrol, 1 : 3); ν max /cm - Tetrabutylammonium hydrogensulfate (10 mg, 2.9 µmol) was added followed by 1,5-dibromopentane (2.4 mL, 4.1 g, 17.0 mmol), and the mixture was heated at reflux overnight. The mixture was allowed to cool and partitioned between water and diethyl ether. The layers were separated and the aqueous layer was re-extracted with diethyl ether (3 × 20 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated to an oil which was purified by column chromatography on silica (eluting with ethyl acetate-petrol, 10 : 90 → 30 : 70). 
R)-Mosher's ester of (R)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol (9b). (R)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol

8-(Triisopropyl-silyloxy)-2-methylene-octan-1-ol (16).
To anhydrous diethyl ether (20 mL) was added n-butyllithium (40 mL of a 2.5 M solution in hexane, 100 mmol) under N 2 , and the resulting solution was cooled to -78 °C. Freshly distilled tetramethylethylenediamine (15.0 mL, 11.5 g, 100 mmol) was added dropwise and the mixture was allowed to stand for 10 min. Methallyl alcohol (4.18 mL, 3.58 g, 49.7 mmol) was added dropwise, and the mixture was stirred overnight and allowed to warm to room temperature. After recooling to -78 °C, 1-bromo-5-(triisopropyl-silyloxy)-pentane 15 (10.0 g, 31.0 mmol) in THF (15 mL) was added dropwise. The mixture was stirred for 1 h with warming to room temperature, and aqueous HCl (0.5 M, 50 mL) was added cautiously. The mixture was partitioned between water and diethyl ether, and the aqueous layer was re-extracted with diethyl ether (3 × 50 mL). The combined organic layers were dried (MgSO 4 ), and concentrated to a residue which was purified by column chromatography on silica (eluting with ethyl acetate-petrol, 5 : 95 → 10 : 90). 
